G. Gruia

3.6k total citations · 1 hit paper
7 papers, 2.8k citations indexed

About

G. Gruia is a scholar working on Oncology, Molecular Biology and Surgery. According to data from OpenAlex, G. Gruia has authored 7 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 4 papers in Molecular Biology and 3 papers in Surgery. Recurrent topics in G. Gruia's work include Cancer therapeutics and mechanisms (4 papers), Colorectal Cancer Treatments and Studies (3 papers) and Hepatocellular Carcinoma Treatment and Prognosis (3 papers). G. Gruia is often cited by papers focused on Cancer therapeutics and mechanisms (4 papers), Colorectal Cancer Treatments and Studies (3 papers) and Hepatocellular Carcinoma Treatment and Prognosis (3 papers). G. Gruia collaborates with scholars based in France, Belgium and Netherlands. G. Gruia's co-authors include Matilde Navarro, P Jandı́k, J Carmichael, Timothy Iveson, Lucile Awad, Petr Karásek, May Alakl, AD Roth, David Cunningham and P Rougier and has published in prestigious journals such as The Lancet, Annals of Oncology and European Journal of Cancer.

In The Last Decade

G. Gruia

7 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

2000 2.5k citations J-Y Douillard, David Cunningham et al. The Lancet profile →

Peers

Countries citing papers authored by G. Gruia

Since Specialization

Citations

This map shows the geographic impact of G. Gruia's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G. Gruia with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G. Gruia more than expected).

Fields of papers citing papers by G. Gruia

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by G. Gruia. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G. Gruia. The network helps show where G. Gruia may publish in the future.

Co-authorship network of co-authors of G. Gruia

This figure shows the co-authorship network connecting the top 25 collaborators of G. Gruia. A scholar is included among the top collaborators of G. Gruia based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G. Gruia. G. Gruia is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

#	Work	Indexed citations
1	Continuous infusion of hepatic arterial irinotecan in pretreated patients with colorectal cancer metastatic to the liver 2003 ·Annals of Oncology ·J.M.G.H. van Riel, C.J. van Groeningen, Jacques De Grève, G. Gruia, H. M. Pinedo, Giuseppe Giaccone	39
2	Continuous administration of irinotecan by hepatic arterial infusion: a phase I and pharmacokinetic study. 2002 ·PubMed ·J.M.G.H. van Riel, Cees J. van Groeningen, (unknown), Helen Gall, (unknown), G. Gruia, Herbert M. Pinedo, W. J. F. van der Vijgh, Giuseppe Giaccone	52
3	Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial breakdown → 2000 ·The Lancet ·J-Y Douillard, David Cunningham, AD Roth, Matilde Navarro, (unknown), Petr Karásek, P Jandı́k, Timothy Iveson, J Carmichael, May Alakl, G. Gruia, Lucile Awad, P Rougier	2530
4	Treatment With a Nonanthracycline Regimen in Advanced Breast Cancer 1999 ·American Journal of Clinical Oncology ·(unknown), Aňa Lluch, (unknown), G. Gruia, Antonio Llombart‐Cussac, Ricardo Fernández, F.M. Delgado, (unknown)	1
5	Dose-finding study of docetaxel and doxorubicin in first-line treatment of patients with metastatic breast cancer 1999 ·Annals of Oncology ·J. L. Misset, Véronique Dièras, G. Gruia, Hugues Bourgeois, Esteban Cvitkovic, Salima Kalla, Laurence Bozec, Philippe Beuzeboc, C Jasmin, (unknown), A. Riva, N. Azli, P Pouillart	106
6	Irinotecan (Iri) in combination with high-dose infusional (HDI) 5FU/FA either weekly or bi-weekly: evidence of survival advantage and quality of life (QoL) improvement in metastatic colorectal cancer (MCRC) 1999 ·European Journal of Cancer ·P Rougier, David Cunningham, A Roth, J.R. Germà, R.D. James, Petr Karásek, P Jandı́k, Timothy Iveson, Joseph C. Carmichael, G. Gruia, May Alakl, (unknown), Jean‐Yves Douillard	1
7	A phase II study of irinotecan alternated with five days bolus of 5-fluorouracil and leucovorin in first-line chemotherapy of metastatic colorectal cancer 1998 ·Annals of Oncology ·Eric Van Cutsem, Carmelo Pozzo, Hans Starkhammar, Luc Dirix, E. Terzoli, F. Cognetti, Yves Humblet, Carlo Garufi, Ludo Filez, G. Gruia, Claudia Côté, Carlo Barone	38

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact